CDG is a group of genetic diseases caused by defects in enzymes in the glycosylation process, which are responsible for adding sugar chains to biomolecules such as proteins and lipids within cells. When the function of these enzymes is impaired, it leads to insufficient or abnormal glycosylation, affecting various biological processes such as intercellular signal transmission, cell adhesion, and cell recognition. In the gastrointestinal tract, this abnormality leads to impaired intestinal mucosal cell function and the occurrence of gastrointestinal diseases.
CDG often causes a series of gastrointestinal diseases including protein-losing enteropathy, liver disease due to abnormal glycosylation of liver enzymes, chronic diarrhea, malabsorption syndromes, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colitis, and gastric cancer.
CD BioGlyco is committed to providing comprehensive and advanced Glycobiology Disease Model Development Services. We specialize in providing Glycobiology Disease Model Construction Services, using these models to understand disease mechanisms and develop new treatments and drug screening. We are committed to building comprehensive and accurate CDG-related gastrointestinal disease models. Each model type is designed to deepen our understanding of disease and promote effective drug discovery and development.
We use technologies like CRISPR-Cas9 to manipulate genetic material to produce studyable disease phenotypes. By culturing cells in vitro, we manipulate their conditions and study key aspects of CDG-related cell behavior, molecular interactions, gene expression, and drug response.
We use transgenesis or genome editing to create animal models that resemble human CDG. We use transgenic technology or tools such as CRISPR-Cas9 to introduce human gene mutations into animal models, leading to corresponding disease phenotypes. We use animals such as mice, rats, or pigs models to study the pathology of gastrointestinal diseases. We study disease pathogenesis and test new drug candidates using these models.
We build organoid models using stem cells and a 3D matrix that facilitates growth. They involve isolating stem cells, stimulating their differentiation into desired cell types, and embedding them in a matrix that provides a three-dimensional growth environment. These 3D tissue cultures have become more accurate tools for modeling gastrointestinal diseases. We create organoids from primary tissues or pluripotent stem cells to mimic the complex structure and multicellular environment of organs.
Ex vivo model construction involves microdissection and biopsy to obtain tissues from animal or human sources. We then select precision-cut tissue sectioning and perfuse organ techniques to help maintain a near-physiological environment. Unlike traditional in vitro models, ex vivo models maintain conditions that more closely resemble the in vivo environment. By culturing and examining tissues outside their natural environment, we more accurately control and study tissue-specific responses.
We rely on obtaining tissue directly from animals or donors. These may involve biopsies of fresh tissue or histological studies of preserved tissue. Subsequently, isolation of primary cells or cultures is performed in appropriate media. These models provide insights into specific disease responses in animals and humans. Access to normal and diseased tissues helps us study tissue-specific cellular interactions and pathogenesis.
Technology: Establishment of human intestinal enteroids (HIEs) cells from patient tissues and N-glycoproteomic analyze
Journal: Glycobiology
IF: 4.3
Published: 2024
Results: Using a bottom-up glycoproteomic approach, the researchers defined and compared N-linked glycans of glycoproteins extracted from seven different jejunal HIEs. First, they procured HIE cells from patient tissue, gathering differentiated jejunal HIE cells from six separate individuals, including J4 HIE, which was transduced with the FUT2 gene. Following this, they extracted membrane proteins and enriched the glycopeptides through hydrophilic interaction liquid chromatography, which they then subjected to nanoLC-MS/MS analysis. The researchers discovered a total of 694 unique glycopeptides from 93 different glycoproteins. Interestingly, polyfucosylated HBGA-containing glycopeptides were most prominent in four distinct glycoproteins: tetraspanin-8, the carcinoembryonic antigen-related cell adhesion molecule 5, sucrose-isomaltase, and aminopeptidase N.
Fig.1 Major complex-type glycopeptides. (Nilsson, et al., 2024)
Yes, we also provide our clients with comprehensive one-stop gastrointestinal disease research. Our commonly used sample types include tissue samples, blood samples, serum samples, saliva samples, stool samples, mucosal samples, urine samples, etc.
Our team provides comprehensive experimental data to support research. This includes genetic sequencing data confirming successful gene editing, histological and biochemical data demonstrating phenotypic changes in model organisms, and efficacy data from preclinical drug testing. In addition, we provide clients with detailed reports on model growth characteristics, clinical observations, behavioral analysis, and biomarker validation results. Taken together, our detailed data support clients in understanding disease pathogenesis and evaluating potential interventions.
At CD BioGlyco, we employ a range of disease modeling methods, each tailored to suit different research aspects. Our commitment to continuously refining our models and technologies ensures that we make substantial strides in understanding gastrointestinal diseases related to CDG. Please feel free to contact us if you are interested in our gastrointestinal disease model construction service.
Reference
